Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Pharma tightens its belt on jobs in 2016 as markets fall
Big pharma swings the axe as sales per employee falls and big biotech could be forced to follow suit.
Patent rulings knock Acorda and Forward
Acorda and Forward have been bashed by unfavourable US patent verdicts in multiple sclerosis, while Steadymed got a boost.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.